SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.

   Microcap & Penny Stocksjerseyfish penny stocks


Previous 10 Next 10 
From: Jerseyfish11/18/2018 1:59:05 PM
   of 1978
 
Its all coming together and the place to be invested.


Share RecommendKeepReplyMark as Last Read


From: Jerseyfish11/25/2018 6:03:15 PM
   of 1978
 
RMHB -
Forget THC! Cannabidiol (CBD) Is the Marijuana Industry's Moneymaker The CBD market could offer a compound annual growth rate of 147% through 2022.




Sean Williams
( TMFUltraLong)


Nov 24, 2018 at 9:06AM



Ready or not, legal marijuana is taking North America by storm. Even though the U.S. federal government has held firm on marijuana as a Schedule I drug (i.e., entirely illegal, prone to abuse, and not recognized as having any medical benefits), we've nevertheless witnessed 32 states legalize medical weed in some capacity. To our south, Mexico legalized medical pot in the summer of 2017 and is now strongly considering legalizing adult-use weed. And to our north, on Oct. 17, Canada became the first industrialized country in the world to give the green light to recreational cannabis.

According to investment firm Cowen Group, which has been one of the most optimistic Wall Street firms on the outlook for global cannabis, the industry could hit $75 billion in annual sales by 2030. This pie-in-the-sky sales figure is a big reason behind the lofty valuations of most marijuana stocks.


Image source: Getty Images.


But what investors may not realize is that not all cannabis is created equally. Just as no two marijuana stocks are the same, neither are the prospects for different cannabis products. Whereas the world is eyeing sales of dried cannabis flower that's rich with tetrahydrocannabinol (THC), the cannabinoid responsible for getting a user "high," I believe it's the other important cannabinoid known as cannabidiol (CBD) that'll ultimately be the big moneymaker for pot stocks.

CBD is where the big money is Cannabidiol, like THC, comes from the cannabis plant (although CBD can also be found in abundance via hemp). However, CBD doesn't get a user high. Rather, it's best known for its perceived medical benefits.

For example, GW Pharmaceuticals ( NASDAQ:GWPH) earlier this year became the first drug developer to have the U.S. Food and Drug Administration approve a cannabis-derived therapy. Epidiolex, as it's known, is an oral CBD-based medicine that's designed to treat two rare forms of childhood-onset epilepsy. In clinical trials, GW Pharmaceuticals' lead drug wound up significantly reducing seizure frequency from baseline relative to a placebo. Eventual sales of GW Pharmaceuticals' top drug may top $500 million annually, but that will, of course, depend on insurer coverage and the willingness of physicians to prescribe Epidiolex.


The thing is, CBD isn't just limited to cannabinoid-based drugmakers. Marijuana growers can incorporate CBD into oils, capsules, pills, vapes, infused beverages, edibles, and pretty much any alternative form of consumption you can think of. It's worth noting, though, that with the exception of oils, alternative forms of consumption are currently illegal in Canada. However, Parliament is widely expected to discuss and approve new consumption options by next summer.


Image source: Getty Images.


According to the Brightfield Group, a cannabis analytics firm, the CBD market is on track to generate $591 million in sales in 2018. However, by 2022, hemp-CBD sales are projected to reach... drumroll... $22 billion. For you math-phobes out there, this represents a compound annual growth rate of 147% over the next four years.

What's more, CBD-rich products tend to be a considerably higher-margin item than traditional dried cannabis flower. Though focused on a smaller group of consumers than dried flower, CBD products have little in the way of pricing pressures or oversupply concerns.

These pot stocks are focusing on CBD products In other words, marijuana stocks that incorporate CBD products into their portfolios have a much better opportunity to improve their operating margins over the long run, as well as avoid any pricing pressures caused by an oversupply of dried flower.


Not surprisingly, one such company that's made a concerted effort to develop alternative products is Aurora Cannabis ( NYSE:ACB), the projected top dog in peak production. Once its acquisition of ICC Labs is complete, Aurora Cannabis could be on track for 700,000 kilograms of peak annual output. However, Aurora's acquisition of Saskatchewan-based CanniMed Therapeutics brings into the fold an oils processing facility with a design capacity of 720,000 liters of annual oil production. It's also partnered with Capcium -- and allowed Capcium to set up shop at its Aurora Vie facility -- to produce softgel capsules. These softgels could be pivotal in pushing Aurora's margins higher in the years that lie ahead.



Share RecommendKeepReplyMark as Last Read


From: Jerseyfish11/28/2018 5:39:58 AM
   of 1978
 
youtu.be

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish11/28/2018 9:16:57 AM
   of 1978
 
Rocky Mountain High Brands Makes History as the Sole Provider of CBD-Infused Beverages in Mexico and Welcomes Alejandro Montano Urdaneta, Director of International Business for CBD Life, to Its Weekly Podcast

GlobeNewswireNovember 28, 2018

DALLAS, Nov. 28, 2018 (GLOBE NEWSWIRE) -- In a new major development, Rocky Mountain High Brands (RMHB) has been granted permission to be the sole provider of high-quality drinks containing cannabidiol (CBD) to be sold throughout Mexico by RCH Grupo’s subsidiary, CBD Life. It is the first time an American company has manufactured a hemp product in the form of beverages for sale in Mexico.

RMHB’s line of drinks include Rocket High, an energy drink infused with CBD, and CBD-infused California Lemonade and California Black Tea. All beverages were developed by Rocky Mountain High Brands for RCH Grupo’s subsidiary, CBD Life. RMHB’s six new beverages contain a low level of cannabidiol, otherwise known as CBD.

The Company also released its most recent podcast, recorded on November 27, 2018. Mr. Alejandro Montano, Director of International Business for CBD Life, joined RMHB President and CEO Michael Welch and Director of Operations Christian Vega to address the issuance of the permits and their effect on the Company. In the podcast, Mr. Montano also cleared up the confusion concerning the RMHB’s contract executed with RCH Grupo’s subsidiary, CBD Alimentos, and the recent permits issued to RCH Grupo’s subsidiary, CBD Life. To view the podcast, please click on the following link:

https://www.youtube.com/watch?v=658U6p87s9k

Mr. Janko Ruiz de Chávez, Chief Operations Officer of CBD Life, stated, “Rocket High, California Lemonade and California Black Tea will be available in supermarkets and other businesses throughout Mexico early in the first quarter of 2019.”

Michael Welch, President and Chief Executive Officer of Rocky Mountain High Brands, stated, “We are very proud of the efforts our Team Mexico made in the development of the Rocket High and the California beverages. We believe that the beverages have great potential in Mexico and other countries.”

The Mexican government recently approved the importation and sale of CBD products in retail establishments across Mexico. CBD Life was granted 21 distribution licenses, which include the licenses for the drinks produced exclusively by Rocky Mountain High Brands.

Mr. Ruiz de Chávez continued, “CBD Life chose Rocky Mountain High Brands because we felt that working with their strong leadership team, especially their Project Team Leader Christian Vega, was a good fit for us. Mr. Vega understands both cultures, how business is conducted in both countries, and is the driving force behind the success of this project. We knew that Rocky Mountain High Brands and Mr. Vega would follow high standards and would not cut corners. They will produce a high-quality product at a reasonable price for our company.”

“This was a very selective process,” said Christian Vega, Rocky Mountain High’s Director of Operations. “No other company has done this before. We went the distance amid challenges over the course of a year, and are very proud of the beverages we created.”

About Rocky Mountain High Brands:

ROCKY MOUNTAIN HIGH BRANDS, INC., (RMHB) is a publicly-traded, lifestyle brand management company that markets “good for you” products to health-conscious consumers.

We are committed to empowering, motivating and inspiring healthy lifestyle habits that create a positive impact on everyday people. We reach those people with our brand messages and change people’s lives with our products. Our products inspire people to choose wellness and healthy lifestyles.

Our mission is to help people live more productive and healthier lives.

The Company currently markets a lineup of two naturally flavored hemp-infused functional beverages under the name Rocky Mountain High. RMHB also bottles and distributes a naturally high alkaline spring water under the name Eagle Spirit Spring Water. In March 2018, the Company launched its HEMPd product line, which currently consists of CBD-infused topicals and nutraceuticals. The Company will introduce a line of CBD-infused functional beverages in the fourth quarter. The Company recently acquired FitWhey, a unique water-based protein drink that is naturally sweetened, flavored and colored that combines the highest quality whey protein isolate with caffeine. RMHB continues to be innovative through R&D and bringing new products to market.

Our vision is to create and sell “good for you” products that touch people in fun, unique and relevant ways.

For interested investors, our stock symbol is RMHB.

For corporate information, please visit: RockyMountainHighBrands.com

Facebook: https://www.facebook.com/rockymountainhighbrands?fref=nf

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish11/28/2018 1:52:04 PM
   of 1978
 
If you are interested in an investment that will continue to grow consider Rocky Mountain High Brands, (RMHB). This is a company that provide health products in the form of Drinks and eatables and is going international. Its a start up operation and going strong in Mexico and soon to be Europe and on from there. They already have inquires from several South America Countries. The potential for this company to be a monster is great. Currently selling for about a penny a share so the risk is low and the potential is huge.

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish11/29/2018 10:03:37 AM
   of 1978
 
Rocky Mountain High Brands, (RMHB), Interview.
To view the interview, please click on the following link:

dropbox.com

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish12/1/2018 5:44:14 AM
   of 1978
 
Say hello to the new up and coming star.

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish12/3/2018 7:37:07 AM
   of 1978
 
News: Aurora Cannabis Announces Market Launch of Softgel Capsules
2018-12-03 07:00:00 AM ET (PR Newswire)

Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that, further to its October 17, 2018 announcement that it had received a sales license from Health Canada permitting the sale of cannabis softgel capsules, the Company has commenced shipments for both the Canadian medical and adult-use markets. Aurora expects to commence exports to international markets in early 2019.

At scale, the Company anticipates that softgel production at its state-of-the-art Aurora Vie facility in Quebec will reach at least 1.4 million capsules per week. Aurora intends to make this high-volume, high-margin, smoke-free, product available to all of its domestic and international target markets over time where legally possible.

Aurora's softgel capsules are produced to pharmaceutical-grade standards at Aurora Vie, in collaboration with leading softgel manufacturer Capcium Inc. ("Capcium"), in which Aurora holds a 19.99% ownership interest. The Company will initially launch the capsules to the medical cannabis market in Canada as well as the adult-use market in British Columbia with additional provincial markets to follow.

The Company is initially launching four softgel product types, each available in bottles of 30 capsules, priced at $45 per bottle. The small, easy to digest soft gelatin capsules are colour-coded to distinguish between the different varieties for the protection of public health and safety. They are believed to the smallest cannabis capsules on the market. Aurora's softgels provide a dosage-controlled format that medical practitioners and consumers around the world need to facilitate more precise administration.

For the medical market, Aurora is launching three product types:

Aurora Indica Softgels: 8-10 mg/pill of THC Aurora Sativa Softgels: 8-10 mg/pill of THC?Aurora CBD Softgels: 8-10 mg/pill of CBD

For the BC consumer market, one product type will be available initially:

Aurora Liquid Gels: 8-10 mg/pill of CBD, targeted at the non-prescription wellness segment of the market

Additional product types and potencies will be made available in the coming months including softgel capsules that contain 5mg THC, 20mg CBD and 1:1 (5gm CBD and 5mg THC), plus softgels that employ a range of functional carrier oils.

Management Commentary

"Softgels are a high-volume, high-margin product for both the medical and adult-use markets that are in strong demand, and Aurora is one of few companies making these products available to patients and consumers alike," said Terry Booth, CEO of Aurora. "There is a strong momentum towards smoke-free, consistent dosage delivery technologies, and our softgels are a very familiar form factor that satisfy patient and consumer needs. We are delighted to have a preferred partnership with Capcium, whose technology is performing above our initial expectations, delivering high volumes of pharma-grade products."

Shane Morris, SVP Product Development and Regulatory Affairs, added, "Following our successful receipt of our sales license for softgels, we are now ready to start providing yet another type of delivery technology for our patients and customers. Production will be scaling up in the coming weeks, which will enable us to introduce this product to all our domestic and international target markets. We will also continue to develop new types of softgel products, broadening our offering to meet all medical and consumer needs."

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 21 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high- quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to Aurora's rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC - Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

Share RecommendKeepReplyMark as Last Read


From: Jerseyfish12/17/2018 7:36:22 AM
   of 1978
 
The big event for the week and year is the signing of the Farm Bill by the president. It opens the borders between the States and Countries for the sale and us of CBDs and Hemp. Farmers will be able to grow Hemp and feed the supply. Big Investors like Coke and Pepsi will lose the fear and buy into companies looking for money and recognition so they can grow. This is going to be a great Christmas.


Share RecommendKeepReplyMark as Last Read


From: Jerseyfish12/21/2018 5:51:37 AM
   of 1978
 
facebook.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10